Marinomed Biotech AG (VIE: MARI)

Market Cap	8.35M
Revenue (ttm)	6.60M
Net Income (ttm)	-6.87M
Shares Out	1.54M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	17.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	5.42
Previous Close	5.42
Day's Range	5.42 - 5.42
52-Week Range	2.00 - 42.40
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 6, 2024

About Marinomed Biotech AG

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. The company operates through Virology, Immunology, and Other segments. Its products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen for viral pneumonia, as well as Carragelose, which consists of nasal and thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 52
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MARI

Financial Performance

In 2022, GAGS's revenue was 446,000, an increase of 3.00% compared to the previous year's 433,000. Earnings were 1.96 million, an increase of 42.24%.